Close

Clinical Hold on Achillion's (ACHN) Sovaprevir 'Looks Resolvable' - Leerink Swann

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BSX
8. PI
9. NOW
10. ORCL


Go back to Clinical Hold on Achillion's (ACHN) Sovaprevir 'Looks Resolvable' - Leerink Swann

Maxim Group Downgrades Achillion Pharmaceuticals (ACHN) to Hold

July 2, 2013 7:43 AM EDT

Maxim Group downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to Hold.

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $8.36 yesterday, with a 52 week range of $5.42-$11.36.... More

Achillion (ACHN) Down 20%+ on Resumption

July 1, 2013 4:36 PM EDT

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) shares are getting hit on resumption. The stock is down 22 percent.... More

Achillion (ACHN) Peers on Watch Following FDA Clinical Hold for Sovaprevir

July 1, 2013 4:22 PM EDT

Achillion Pharmaceuticals' (Nasdaq: ACHN) hep C rivals are on watch Monday as the U.S. FDA placed a clinical hold on sovaprevir. The FDA said, "elevations... More

FDA Places Clinical Hold on Achillion Pharma's (ACHN) Sovaprevir

July 1, 2013 4:06 PM EDT

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on sovaprevir after elevations in liver enzymes associated with significantly higher than anticipated exposures to atazanivir and sovaprevir were noted in a Phase 1 healthy subject drug-drug interaction (DDI) study evaluating the effects of concomitant administration of sovaprevir with ritonavir-boosted atazanavir. The FDA has allowed continued enrollment and treatment of patients in the Phase 2 -007 clinical... More